Prodrug–carboxypeptidase G2 (CPG2) is a promising anticancer strategy: clinical trials confirm that it can realize a targeted therapy, with a specific advantage of lacking human CPG2 analogues; further, preclinical trials demonstrate that it is effective against chemoresistant ovarian and lung cancers (Sharma and Bagshawe, 2017; Liu et al., 2020; Liu et al., 2022; Yu and Li, 2023; Qoura et al., 2024). Here, SYNE1 is linked to lung carcinoma.